Control of redox regulators by the ubiquitin system

泛素系统对氧化还原调节剂的控制

基本信息

  • 批准号:
    8536839
  • 负责人:
  • 金额:
    $ 30.93万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-09-01 至 2016-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The long-term goal of this research is to reduce the susceptibility of vulnerable cells to the deleterious effects of chronic oxidative stress. Oxidative stress is widely accepted as a primary contributor to a range of pathological conditions including certain cancers, neurodegenerative disorders (e.g., Parkinson's disease and Alzheimer's), diabetic retinopathy, and age-related macular degeneration. The ubiquitin (Ub) proteolytic system (UPS) defends cells against oxidative stress by degrading damaged proteins and by regulating cytoprotective proteins. Paramount among these protective proteins is Nrf2, the master anti-oxidant transcription factor. Oxidative stress activates Nrf2 to induce the expression of anti-oxidant enzymes and factors that restore redox homeostasis. Yet, open questions remain as to the mechanism(s) by which Nrf2 is sequestered on the promoters of its target genes until redox homeostasis is restored. The studies of this application address this critical issue and offer fresh insights into how the UPS contributes to the endogenous antioxidant defense system. The foundation for this work is our recent discovery that the E2 ubiquitin conjugating enzyme, UbcM2, is a novel component of the endogenous oxidative stress response pathway. These findings have led to our overarching hypothesis that UbcM2 is in fact a multi-functional E2. It functions as a redox sensor to enhance the cytoprotective activity of Nrf2 and it plays critical roles in protein degradation and E3 ligase regulation. Three specific aims will be pursued to define the diverse functions of UbcM2. Sp Aim#1: Test the hypothesis that UbcM2 is a redox sensor protein that promotes the cytoprotective activity of Nrf2; Sp Aim#2: Test the hypotheses that UbcM2 regulates Keap1 nuclear import and the affinity of Nrf2 for its cognate response elements in the promoters of anti-oxidant genes. Keap1 is the substrate adaptor that targets Nrf2 for degradation; and Sp Aim#3: Test the hypothesis that UbcM2 regulates substrate adaptor exchange on a class of UPS enzymes called cullin-RING E3 ligases (CRLs). In addition, identify the molecular determinants governing polyUb chain synthesis by UbcM2. The proposed experiments utilize a complementary set of cell culture approaches (e.g., siRNA, microinjection/live cell video microscopy, transcription assays), biochemical and biophysical methods (e.g., recombinant pulldowns, in vitro ubiquitylation assays, mass spectrometry, NMR spectroscopy), and in vivo mouse models of oxidative stress. Together, these studies will: (i) define the molecular mechanisms by which UbcM2 modulates Nrf2 stability and activation, (ii) explore the novel idea that Ub E2s can function as redox sensors to mediate stress response pathways, and (iii) bridge gaps in our understanding of how CRLs exchange substrate adaptors. This information will impact both the UPS and oxidative stress fields by identifying new relationships between E2 function and cellular anti-oxidant defenses.
描述(由申请人提供):本研究的长期目标是降低脆弱细胞对慢性氧化应激有害影响的敏感性。氧化应激被广泛认为是导致一系列病理状况的主要原因,包括某些癌症、神经退行性疾病(例如帕金森病和阿尔茨海默病)、糖尿病性视网膜病和年龄相关性黄斑变性。泛素 (Ub) 蛋白水解系统 (UPS) 通过降解受损蛋白质和调节细胞保护蛋白来保护细胞免受氧化应激。这些保护性蛋白中最重要的是 Nrf2,它是主要的抗氧化转录因子。氧化应激激活 Nrf2,诱导抗氧化酶和因子的表达,恢复氧化还原稳态。然而,关于 Nrf2 被隔离在其靶基因启动子上直到氧化还原稳态恢复的机制仍然存在悬而未决的问题。该应用的研究解决了这一关键问题,并为 UPS 如何促进内源性抗氧化防御系统提供了新的见解。这项工作的基础是我们最近发现 E2 泛素结合酶 UbcM2 是内源性氧化应激反应途径的一个新成分。这些发现得出了我们的总体假设:UbcM2 实际上是一种多功能 E2。它作为氧化还原传感器增强 Nrf2 的细胞保护活性,并在蛋白质降解和 E3 连接酶调节中发挥关键作用。将追求三个具体目标来定义 UbcM2 的多样化功能。 Sp Aim#1:检验 UbcM2 是一种氧化还原传感器蛋白,促进 Nrf2 细胞保护活性的假设; Sp 目标#2:测试 UbcM2 调节 Keap1 核输入的假设以及 Nrf2 与其在抗氧化基因启动子中的同源反应元件的亲和力。 Keap1 是针对 Nrf2 进行降解的底物适配器; Sp 目标#3:测试 UbcM2 调节一类称为 cullin-RING E3 连接酶 (CRL) 的 UPS 酶上的底物接头交换的假设。此外,还确定了控制 UbcM2 多聚泛素链合成的分子决定因素。拟议的实验利用了一组互补的细胞培养方法(例如,siRNA、显微注射/活细胞视频显微镜、转录测定)、生化和生物物理方法(例如,重组下拉、体外泛素化测定、质谱、核磁共振波谱)和体内氧化应激小鼠模型。总之,这些研究将:(i)定义 UbcM2 调节 Nrf2 稳定性和激活的分子机制,(ii)探索 Ub E2s 可以作为氧化还原传感器介导应激反应途径的新想法,以及(iii)弥合我们对 CRL 如何交换底物适配器的理解的差距。该信息将通过识别 E2 功能和细胞抗氧化防御之间的新关系来影响 UPS 和氧化应激场。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Scott M Plafker其他文献

Scott M Plafker的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Scott M Plafker', 18)}}的其他基金

Interrogating the intersection between diet and ocular autoimmunity
探究饮食与眼部自身免疫之间的交叉点
  • 批准号:
    10419170
  • 财政年份:
    2022
  • 资助金额:
    $ 30.93万
  • 项目类别:
Interrogating the intersection between diet and ocular autoimmunity
探究饮食与眼部自身免疫之间的交叉点
  • 批准号:
    10597231
  • 财政年份:
    2022
  • 资助金额:
    $ 30.93万
  • 项目类别:
Treatment strategies for autoimmune demyelinating optic neuritis
自身免疫性脱髓鞘性视神经炎的治疗策略
  • 批准号:
    9249047
  • 财政年份:
    2016
  • 资助金额:
    $ 30.93万
  • 项目类别:
OKHSC COBRE: THE ROLE OF THE UBIQUITIN SYSTEM IN RETINAL DEGENERATION
OKHSC COBRE:泛素系统在视网膜变性中的作用
  • 批准号:
    8360280
  • 财政年份:
    2011
  • 资助金额:
    $ 30.93万
  • 项目类别:
Control of redox regulators by the ubiquitin system
泛素系统对氧化还原调节剂的控制
  • 批准号:
    8727042
  • 财政年份:
    2011
  • 资助金额:
    $ 30.93万
  • 项目类别:
Control of redox regulators by the ubiquitin system
泛素系统对氧化还原调节剂的控制
  • 批准号:
    8106682
  • 财政年份:
    2011
  • 资助金额:
    $ 30.93万
  • 项目类别:
Control of redox regulators by the ubiquitin system
泛素系统对氧化还原调节剂的控制
  • 批准号:
    8320952
  • 财政年份:
    2011
  • 资助金额:
    $ 30.93万
  • 项目类别:
OKHSC COBRE: PROTECTING THE RETINA FROM OXIDATIVE STRESS
OKHSC COBRE:保护视网膜免受氧化应激
  • 批准号:
    8167973
  • 财政年份:
    2010
  • 资助金额:
    $ 30.93万
  • 项目类别:
OKHSC COBRE: UBIQUITIN IN HYPERGLYCEMIA-INDUCED MESANGIAL CELL HYPERTROPHY
OKHSC COBRE:泛素在高血糖引起的系膜细胞肥大中的作用
  • 批准号:
    7959775
  • 财政年份:
    2009
  • 资助金额:
    $ 30.93万
  • 项目类别:
OKHSC COBRE: UBIQUITIN IN HYPERGLYCEMIA-INDUCED MESANGIAL CELL HYPERTROPHY
OKHSC COBRE:泛素在高血糖引起的系膜细胞肥大中的作用
  • 批准号:
    7721020
  • 财政年份:
    2008
  • 资助金额:
    $ 30.93万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
    Studentship
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 30.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了